Case report: rivaroxaban related nephropathy

Luisa Lemos Costa; Ana Rodrigues; Raquel Pinto; Carla Lima; Tânia Sousa; Helena Viana; Mário Góis; Sérgio Lemos; Andreia Silva

doi:10.34172/jnp.2022.17343

doi: 10.34172/jnp.2022.17343

Abstract View: 1149

Case Report

Case report: rivaroxaban related nephropathy

Luisa Lemos Costa ¹^* , Ana Rodrigues ¹ , Raquel Pinto ¹ , Carla Lima ¹ , Tânia Sousa ¹ , Helena Viana ² , Mário Góis ² , Sérgio Lemos ¹ , Andreia Silva ¹

¹ Nephrology Department, Centro Hospitalar Tondela Viseu, Viseu, Portugal
² Nephrology Department, Centro Hospitalar Universitário Lisboa Central, Lisbon, Portugal

*Corresponding author: Luisa Lemos Costa, Email: luisalemosccosta@gmail.com, 7886@hstviseu.min-saude.pt

Abstract

The characteristics of direct oral anticoagulants (DOACs) make them more appealing for prevention of thromboembolic events than vitamin K antagonists (VKA). Despite that, both classes have been a recognized as a cause of anticoagulant related nephropathy (ARN). Herein we describe a case of a 72-year-old man, with chronic kidney disease (CKD), medicated with rivaroxaban, who presented with acute kidney injury (AKI) and microscopic hematuria. The kidney biopsy revealed anticoagulant related-nephropathy. Rivaroxaban was suspended, the patient showed improvement of renal function and apixaban was prescribed. This case emphasizes the need for careful monitoring of serum creatinine when these drugs are prescribed, especially in high risk groups.

Keywords: Direct oral anticoagulants, Vitamin K antagonists, Anticoagulant related nephropathy

Implication for health policy/practice/research/medical education:

This report highlights the importance of awareness of anticoagulant related nephropathy, especially in patients with risk factors and that it should be suspected whenever eGFR is impaired in a patient taking DOAC.

Please cite this paper as: Costa LL, Rodrigues A, Pinto R, Lima C, Sousa T, Viana H, Góis M, Lemos S, Silva A. Case report: rivaroxaban related nephropathy. J Nephropathol. 2022;11(x):exx. DOI: 10.34172/jnp.2022.xx.

First Name

Last Name

Email Address

Comments

Security code